Biofrontera AG BIFRF
OTC PK
| 03/31/2026 | 03/31/2026 | 09/30/2025 | 09/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -62.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -62.51% |
| Cost of Revenue | -- | -- | -- | -- | -78.59% |
| Gross Profit | -- | -- | -- | -- | -58.33% |
| SG&A Expenses | -- | -- | -- | -- | -24.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | -- | -56.50% |
| Operating Income | -- | -- | -- | -- | -101.56% |
| Income Before Tax | -- | -- | -- | -- | 198.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | -- | -- | -- | 1,039.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -339.13% |
| EBIT | -- | -- | -- | -- | -101.56% |
| EBITDA | -- | -- | -- | -- | -93.63% |
| EPS Basic | -- | -- | -- | -- | 90.86% |
| Normalized Basic EPS | -- | -- | -- | -- | 95.51% |
| EPS Diluted | -- | -- | -- | -- | 90.90% |
| Normalized Diluted EPS | -- | -- | -- | -- | 95.51% |
| Average Basic Shares Outstanding | -- | -- | -- | -- | 128.42% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | 128.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |